DAY 2 - Monday, May 6
SPECIAL SESSION
AREDS2 clarifies role of supplements
for advanced AMD
The addition of the carotenoids, lutein and zeaxanthin, and the omega-3 fatty acids, DHA and EPA, to a supplement formulation does not further reduce the risk of disease progression in age-related macular degeneration, said Emily Y. Chew, MD. » MORE
BLOG FROM ARVO
Editor's blog: Some pearls to garner
from AREDS2 results
The results of the long-awaited Age-Related Eye Disease Study 2 (AREDS2) were officially released Sunday afternoon during a special session at the Association for Research in Vision and Ophthalmology meeting in Seattle—and the study results really did not come as a surprise to most in the eye-care community. » MORE
RETINA
Genetics factor in vitamin D, AMD link
Adequate levels of vitamin D can decrease the risk of age-related macular degeneration, but most markedly in individuals with two risk alleles for the CFH Y402H genotype, said Amy Millen, PhD. » MORE
Ranibizumab curtails blindness long term
Long-term results reveal that intravitreal ranibizumab (Lucentis, Genentech) has made a marked difference in the rates of blindness related to wet age-related macular degeneration (AMD), said Peter Cackett, MB BS. » MORE
GLAUCOMA
High ER stress may contribute to POAG
Primary open-angle glaucoma (POAG) is generally associated with elevations in IOP, and damage to the cells residing within the trabecular meshwork is most likely a contributing factor, said Markus H. Kuehn, PhD. » MORE
DISCLAIMER:
This information has been independently developed and provided by the editors of Ophthalmology Times. The sponsor does not endorse and is not responsible for the accuracy of the content or for practices or standards of non-sponsor sources.
|
